132836-42-1
132836-42-1 structure
- Name: YS-49
- Chemical Name: YS-49 monohydrate
- CAS Number: 132836-42-1
- Molecular Formula: C20H20BrNO2
- Molecular Weight: 386.282
- Catalog: Research Areas Cardiovascular Disease
- Create Date: 2016-06-28 06:11:53
- Modify Date: 2024-01-05 17:24:20
-
YS 49 inhibits Ang II-stimulated proliferation of VSMCs via induction of HO-1.IC50 value:Target: HO-1YS-49 is a novel positive inotropic isoquinoline compound. YS-49 has potential as a therapeutic strategy for the pathogenesis of Ang II-related vascular diseases such as hypertension and atherosclerosis, via the induction of HO-1 gene activity. YS-49 induced HO-1 protein production in a dose-and time-dependent manner in VSMCs. Treatment with YS-49 significantly and dose-dependently inhibited Ang II-induced VSMC proliferation, ROS production, and phosphorylation of JNK, but not P38 MAP kinase or ERK1/2.YS-49(32.8 microM) exhibited much stronger inhibitory effects on TXA(2) formation. The higher inhibitory potencies of YS-49 (IC(50): 3.3microM) than higenamine (IC(50): 140 microM) on AA induced rat platelet aggregation was presumed to be the result of low inhibitory effect of higenamine than YS-49 on TXA(2) production from AA. The oral administration of YS-49 (50 mg/kg) increased the recovery rates from the acute thrombotic challenge in mice and lowered the weight of thrombus formed inside the AV shunt tube in rats.
| Name | YS-49 monohydrate |
|---|---|
| Synonyms |
6,7-Isoquinolinediol, 1,2,3,4-tetrahydro-1-(1-naphthalenylmethyl)-, hydrobromide (1:1)
YS-49 Monohydrate 1,2,3,4-Tetrahydro-1-(1-naphthalenylmethyl)-6,7-Isoquinolinediol hydrobromide monohydrate 1-(naphthalen-1-ylmethyl)-1,2,3,4-tetrahydroisoquinoline-6,7-diol,hydrobromide 1-(1-Naphthylmethyl)-1,2,3,4-tetrahydro-6,7-isoquinolinediol hydrobromide (1:1) YS-49 |
| Description | YS 49 inhibits Ang II-stimulated proliferation of VSMCs via induction of HO-1.IC50 value:Target: HO-1YS-49 is a novel positive inotropic isoquinoline compound. YS-49 has potential as a therapeutic strategy for the pathogenesis of Ang II-related vascular diseases such as hypertension and atherosclerosis, via the induction of HO-1 gene activity. YS-49 induced HO-1 protein production in a dose-and time-dependent manner in VSMCs. Treatment with YS-49 significantly and dose-dependently inhibited Ang II-induced VSMC proliferation, ROS production, and phosphorylation of JNK, but not P38 MAP kinase or ERK1/2.YS-49(32.8 microM) exhibited much stronger inhibitory effects on TXA(2) formation. The higher inhibitory potencies of YS-49 (IC(50): 3.3microM) than higenamine (IC(50): 140 microM) on AA induced rat platelet aggregation was presumed to be the result of low inhibitory effect of higenamine than YS-49 on TXA(2) production from AA. The oral administration of YS-49 (50 mg/kg) increased the recovery rates from the acute thrombotic challenge in mice and lowered the weight of thrombus formed inside the AV shunt tube in rats. |
|---|---|
| Related Catalog | |
| References |
| Molecular Formula | C20H20BrNO2 |
|---|---|
| Molecular Weight | 386.282 |
| Exact Mass | 385.067749 |
| PSA | 52.49000 |
| LogP | 4.96740 |
| Storage condition | 2-8℃ |